ATE384265T1 - Diagnostischer assay mit dem makrophagen- inhibitorischen-zytokin-1 (mic-1) - Google Patents

Diagnostischer assay mit dem makrophagen- inhibitorischen-zytokin-1 (mic-1)

Info

Publication number
ATE384265T1
ATE384265T1 AT01923411T AT01923411T ATE384265T1 AT E384265 T1 ATE384265 T1 AT E384265T1 AT 01923411 T AT01923411 T AT 01923411T AT 01923411 T AT01923411 T AT 01923411T AT E384265 T1 ATE384265 T1 AT E384265T1
Authority
AT
Austria
Prior art keywords
mic
methods
macrophage inhibitory
inhibitory cytokine
diagnostic assay
Prior art date
Application number
AT01923411T
Other languages
English (en)
Inventor
Samuel Breit
David Alexander Brown
Original Assignee
St Vincents Hosp Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ7037A external-priority patent/AUPQ703700A0/en
Priority claimed from AUPQ7465A external-priority patent/AUPQ746500A0/en
Application filed by St Vincents Hosp Sydney filed Critical St Vincents Hosp Sydney
Application granted granted Critical
Publication of ATE384265T1 publication Critical patent/ATE384265T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/195Chemokines, e.g. RANTES
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/101Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
AT01923411T 2000-04-20 2001-04-20 Diagnostischer assay mit dem makrophagen- inhibitorischen-zytokin-1 (mic-1) ATE384265T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ7037A AUPQ703700A0 (en) 2000-04-20 2000-04-20 Diagnostic assay and method of treatment
AUPQ7465A AUPQ746500A0 (en) 2000-05-11 2000-05-11 Diagnostic assay

Publications (1)

Publication Number Publication Date
ATE384265T1 true ATE384265T1 (de) 2008-02-15

Family

ID=25646308

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01923411T ATE384265T1 (de) 2000-04-20 2001-04-20 Diagnostischer assay mit dem makrophagen- inhibitorischen-zytokin-1 (mic-1)
AT07023699T ATE470863T1 (de) 2000-04-20 2001-04-20 Diagnostischer assay mit makrophagenhemmendem zytokin-1 (mic-1)

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07023699T ATE470863T1 (de) 2000-04-20 2001-04-20 Diagnostischer assay mit makrophagenhemmendem zytokin-1 (mic-1)

Country Status (9)

Country Link
US (2) US7514221B2 (de)
EP (2) EP1279039B1 (de)
JP (1) JP4920851B2 (de)
AT (2) ATE384265T1 (de)
AU (2) AU5018201A (de)
CA (1) CA2405680C (de)
DE (2) DE60132442T2 (de)
ES (2) ES2346918T3 (de)
WO (1) WO2001081928A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100475642B1 (ko) * 2001-12-29 2005-03-10 한국생명공학연구원 암 발생 및 전이에 관여하는 단백질의 당쇄 변화를측정하여 암을 진단하는 방법 및 이를 이용한 진단킷트
CA2390820A1 (en) 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
CA2504508A1 (en) * 2002-11-08 2004-05-27 Barnes-Jewish Hospital Methods and compositions for prostate epithelial cell differentiation
US7323346B2 (en) * 2003-08-14 2008-01-29 The General Hospital Corporation Screening for gestational disorders
KR100679666B1 (ko) * 2004-01-20 2007-02-07 한국생명공학연구원 인간 대식세포 억제 사이토카인-1 특이적 단일클론항체,이를 분비하는 하이브리도마 및 이를 포함하는 위암 진단키트
PT2929891T (pt) 2004-04-13 2020-04-08 St Vincents Hospital Sydney Ltd Método para modulação do apetite
AU2005232335B2 (en) * 2004-04-13 2009-09-03 St Vincent's Hospital Sydney Limited Method for modulating appetite
US20070237713A1 (en) 2006-04-04 2007-10-11 Fan Rong A PCan065 Antibody Compositions and Methods of Use
BRPI0715126B8 (pt) 2006-08-04 2021-07-27 Medizinische Hochschule Hannover métodos para avaliação do risco de intervenções cardíacas e usos à base de gdf-15
JP2010540534A (ja) * 2007-09-28 2010-12-24 イントレキソン コーポレーション 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用
US20110039284A1 (en) * 2007-10-22 2011-02-17 Samuel Norbert Breit Methods of prognosis
US20120107420A1 (en) 2008-10-31 2012-05-03 St Vincent's Hospital Sydney Limited Methods of prognosis in chronic kidney disease
GB0902737D0 (en) 2009-02-19 2009-04-01 Univ Gent GDF15 as a differential marker for spondyloarthropathy
GB0902793D0 (en) * 2009-02-20 2009-04-08 Univ Gent GDF15 as molecular tool to monitor and enhance phenotypic stability of articular chondrocytes
US9212221B2 (en) * 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
WO2011112993A2 (en) 2010-03-11 2011-09-15 University Of Louisville Research Foundation, Inc. Methods of predicting and decreasing the risk of pregnancy loss
US20130203624A1 (en) * 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
EP2830646B1 (de) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von stoffwechselerkrankungen
EP2934584B1 (de) 2012-12-21 2020-02-19 Aveo Pharmaceuticals, Inc. Anti-gdf15-antikörper
JP6272907B2 (ja) 2013-01-30 2018-01-31 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害の処置における組成物及び使用方法
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
KR20170065026A (ko) 2014-07-30 2017-06-12 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애 치료용으로 이용되는 조성물 및 방법
MY186702A (en) 2014-10-31 2021-08-11 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
US11604194B2 (en) 2016-02-29 2023-03-14 Public University Corporation Yokohama City University Method for detecting castration-resistant prostate cancer and detection reagent
TWI815793B (zh) 2016-03-31 2023-09-21 美商恩格姆生物製藥公司 結合蛋白質及其使用方法
WO2018187767A1 (en) * 2017-04-06 2018-10-11 The Regents Of The University Of California Predicting, diagnosing, and treating nausea and vomiting of pregnancy
JP7127422B2 (ja) 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬
SG11202006594WA (en) * 2018-01-15 2020-08-28 Univ Nanyang Tech Superhydrophobic platform for sensing urine metabolites and toxins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US59431A (en) * 1866-11-06 Improved door-fastener
WO1994003599A1 (en) * 1992-08-04 1994-02-17 Sagami Chemical Research Center HUMAN cDNA AND PROTEIN WHICH SAID cDNA CODES FOR
US6180602B1 (en) * 1992-08-04 2001-01-30 Sagami Chemical Research Center Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
JPH07250688A (ja) 1994-01-28 1995-10-03 Sagami Chem Res Center TGF−βスーパーファミリー蛋白質をコードするヒト新規cDNA
JPH07258293A (ja) 1994-03-23 1995-10-09 Asahi Chem Ind Co Ltd 新規な蛋白質ならびにその製造方法
US5994102A (en) * 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
WO1996018730A1 (en) 1994-12-15 1996-06-20 Human Genome Sciences, Inc. Prostatic growth factor
US6521227B1 (en) * 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
WO1997000958A1 (en) * 1995-06-22 1997-01-09 St. Vincent's Hospital Sydney Limited NOVEL TGF-β LIKE CYTOKINE
EP1074620A1 (de) * 1999-08-06 2001-02-07 HyGene AG Monomer Protein der TGF-beta Familie
AU8591198A (en) * 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
WO1999021011A1 (en) 1997-10-23 1999-04-29 Fibrogen, Inc. Type ix collagen antibody and related uses
US6465181B2 (en) * 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
WO2000070051A1 (en) * 1999-05-17 2000-11-23 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh NEUROPROTECTIVE PROPERTIES OF GDF-15, A NOVEL MEMBER OF THE TGF-β SUPERFAMILY

Also Published As

Publication number Publication date
AU5018201A (en) 2001-11-07
CA2405680C (en) 2018-02-13
AU2001250182B2 (en) 2006-06-08
EP1914554A2 (de) 2008-04-23
EP1279039A1 (de) 2003-01-29
US20090291889A1 (en) 2009-11-26
ATE470863T1 (de) 2010-06-15
ES2346918T3 (es) 2010-10-21
US20040053325A1 (en) 2004-03-18
DE60132442D1 (de) 2008-03-06
DE60132442T2 (de) 2009-01-22
WO2001081928A1 (en) 2001-11-01
CA2405680A1 (en) 2001-11-01
EP1914554A3 (de) 2008-08-06
US7968303B2 (en) 2011-06-28
JP4920851B2 (ja) 2012-04-18
ES2300325T3 (es) 2008-06-16
DE60142372D1 (de) 2010-07-22
JP2003532079A (ja) 2003-10-28
EP1914554B1 (de) 2010-06-09
US7514221B2 (en) 2009-04-07
EP1279039A4 (de) 2005-05-25
EP1279039B1 (de) 2008-01-16

Similar Documents

Publication Publication Date Title
ATE384265T1 (de) Diagnostischer assay mit dem makrophagen- inhibitorischen-zytokin-1 (mic-1)
HK1208724A1 (en) Evaluating the efficacy of a treatment in a subject based on st2 levels st2
WO2006081473A8 (en) Methods for diagnosis and prognosis of epithelial cancers
WO2005010486A3 (en) Biomarker panel for colorectal cancer
EP1895302A3 (de) Verfahren zum Nachweis von kolorektalem Krebs in menschlichen Proben
DK1439897T3 (da) Fremgangsmåder til adskillelse af sjældne celler fra væskeprøver
WO2001040517A3 (en) Evaluating and predicting clinical outcomes by gene expression analysis
DE60325628D1 (de) Gene und polypeptide in verbindung mit menschlichen pankreaskarzinomen
AU7494701A (en) Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2006113210A3 (en) Diagnostic multimarker serological profiling
WO2003073910A3 (en) Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples
HK1089511A1 (en) Hemoglobin assay for neonatal screening
DE602005022709D1 (de) Quantifizierungsverfahren für die vegf isoformen einer biologischen probe
WO2002102229A3 (en) Diagnosing tumorigenicity and determining resistance to anticancer therapy
WO2004031414A3 (en) Method for diagnosing prostate cancer
WO2004021008A3 (en) Methods for detecting breast and ovarian cancer
WO2003044485A3 (en) Proteonomic methods for diagnosis and monitoring of breast cancer
ATE272214T1 (de) Verfahren zur diagnose von sepsis unter bestimmung von s100b
WO2002092858A3 (en) Methods of screening for disease
WO2002010456A3 (en) Multiparameter analysis for predictive medicine
WO2002059611A3 (en) Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides
NO20034059L (no) Fremgangsmate for screening av pre-diabetiske tilstander og screening-reagens
BRPI0415562A (pt) reagente para avaliação diagnóstica e/ou prognóstica de carcinoma, métodos para determinação de p-lap que é um fator prognóstico em carcinoma, e para avaliação prognóstica de carcinoma, e, kit de imunoensaio para determinação da quantidade de p-lap presente em tecidos de carcinoma
PT1297342E (pt) Metodo de diagnostico para a doenca de alzheimer com base em holo-transcobalamina ii
NO20042472L (no) Lys-styrt molekylaer analyse for kreftprognose og diagnose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1279039

Country of ref document: EP